Journal profile · Pharmacology & Pharmacy
Biopharmaceutics & Drug Disposition
ISSN 0142-2782 · eISSN 1099-081X · Wiley · ENGLAND · Bi-monthly · Founded 1979
Biopharmaceutics & Drug Disposition: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.11; hybrid open access; APC about USD 3,800; median 175 days to acceptance (38 articles, last 24 months); community-reported acceptance: fairly easy; 31 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Biopharmaceutics & Drug Disposition is published by Wiley and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Drug Transport and Resistance Mechanisms, Pharmacogenetics and Drug Metabolism and Antibiotics Pharmacokinetics and Efficacy, together about 40.7% of its articles. Its main subfields are Pharmacology. (generated from OpenAlex topic counts and CAS ranking data)
Biopharmaceutics & Drug Disposition publishes original review articles, short communications, and reports in biopharmaceutics, drug disposition, pharmacokinetics and pharmacodynamics, especially those that have a direct relation to the drug discovery/development and the therapeutic use of drugs. includes animal and human pharmacological studies that focus on therapeutic response, pharmacodynamics, and toxicity related to plasma and tissue concentrations of drugs and their metabolites in vitro and in vivo drug absorption, distribution, metabolism, transport, and excretion studies that facilitate investigations related to the use of drugs in man studies on membrane transport and enzymes, including their regulation and the impact of pharmacogenomics on drug absorption and disposition simulation and modeling in drug discovery and development theoretical treatises includes themed issues and reviews The journal excludes manuscripts on: bioavailability studies reporting only on simple PK parameters such as Cmax, tmax and t1/2 without mechanistic interpretation analytical methods purely biological or pharmacological studies that do not have any linkage to drug or metabolite concentrations molecule docking, structure biology, computation chemistry clinical case study Reports must contain current citation of the literature and convey new information. Biopharmaceutics & Drug Disposition is one of the top accessed and cited journals in the field, as a result of the high quality papers published in the journal, and is marketed by Wiley across the world.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Dongyang LiuPublisher website
Editorial board by country: 4 in mainland China (about 10%); most named United States 12, Japan 7, Canada 5, Mainland China 4, United Kingdom 4 (39 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Drug Transport and Resistance MechanismsMedicine15.9%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics14.3%
- Antibiotics Pharmacokinetics and EfficacyMedicine10.5%
- Analytical Methods in PharmaceuticalsChemistry7.4%
- Pharmacological Effects and Toxicity StudiesMedicine6.9%
- Pharmaceutical studies and practicesMedicine3.9%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics3.7%
- Analytical Chemistry and ChromatographyChemistry3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASCAB AbstractsCurrent ContentsPublisher website
Other: ProQuest
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.11LetPub ·
- Impact factor (publisher)
- 2.2Publisher website ·
- Impact factor (publisher) 2025
- 2.2Publisher website ·
- CiteScore 2026-06
- 4.2LetPub ·
- CiteScore (publisher)
- 4.2Publisher website ·
- CiteScore (publisher) 2025
- 4.2Publisher website ·
- SJR 2026-06
- 0.54LetPub ·
- SNIP 2026-06
- 0.68LetPub ·
- h-index
- 54LetPub ·
- h-index
- 80OpenAlex ·
- i10-index
- 1,246OpenAlex ·
- 2-year mean citedness
- 1.51OpenAlex ·
- Self-citation rate
- 4.5%LetPub ·
- Share of gold OA articles
- 22.73%LetPub ·
Volume
- Articles per year
- 20LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 21Publisher website ·
- Downloads per year (publisher) 2025
- 78,928Publisher website ·
Articles by year OpenAlex count · 3,056 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 19 | 6 | 5 |
| 2025 | 31 | 13 | 26 |
| 2024 | 24 | 15 | 81 |
| 2023 | 43 | 18 | 236 |
| 2022 | 41 | 9 | 289 |
| 2021 | 52 | 12 | 330 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
175 daysMedian, submission to acceptance · P25–P75 117 days – 232 days
- Acceptance to online
- median 14 days (38 articles)
- Submission to online
- median 188 days
- Sample
- 38 articles with submission and acceptance dates (47 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 13%Publisher website ·
- Acceptance rate (publisher) 2025
- 13%Publisher website ·
- Submission to first decision
- 43 daysPublisher website ·
- Submission to first decision 2025
- 43 daysPublisher website ·
- Submission to acceptance 2025
- 169 daysPublisher website ·
- Acceptance to publication 2025
- 13 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,800 / EUR 3,170 / GBP 2,550 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≥ 3
- Manuscript length
- ≤ 5,000 words
- Reference style
- APA
- First submission
- Free format: the journal's layout is not required
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted9, with length limits
- commentariesThe journal publishes original articles, reviews, short communications, commentaries and editorials.Length not stated
- commentaryWord limit: 1,500 words maximum excluding references.Abstract: not required.References: 20 maximum, including the article discussed.Figures/tables: 2 maximum.No…main text ≤ 1,500 words
- editorialThe journal publishes original articles, reviews, short communications, commentaries and editorials.Length not stated
- letter to the editorWord limit: 400 words maximum excluding references, tables and figures. Abstract: No abstract is needed.References: 5 maximum.Figure/table: 1 maximum.Descriptio…main text ≤ 400 words
- original articleWord limit: 5,000 words maximum including abstract but excluding references, tables and figures.Abstract: 250 words, structured with sections of Introduction, M…main text ≤ 5,000 words · abstract ≤ 250 words
- original articlesThe journal publishes original articles, reviews, short communications, commentaries and editorials.Length not stated
- reviewWord limit: 8,000 words maximum, excluding references, tables and figures.Abstract: 250 words, unstructured. 3-5 keywords (MeSH terms) are also required.Referen…main text ≤ 8,000 words · abstract ≤ 250 words
- short communicationWord limit:1,500 words maximum including abstract but excluding references, tables and figures.Abstract: Structured.References: 20 maximum.Figures/tables: 2 max…main text ≤ 1,500 words
- short communicationsThe journal publishes original articles, reviews, short communications, commentaries and editorials.Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Data availability, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- Authorship Authorship
Each author must declare his or her role on the submitted work. All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review editorial standards for a description of authorship criteria.
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest Declaration
All authors must disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of confli…
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
Data sharing expected; authors should include a data accessibility statement with repository link. Model summary
The journal expects authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper. Review Wiley’s Data Sharing policy where you will be able to see and s…
Source ↗Publisher website ·- License & copyright 6. COPYRIGHT, LICENSING AND OPEN ACCESS
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to log into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.
Source ↗Publisher website ·- Open access 6. COPYRIGHT, LICENSING AND OPEN ACCESS
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to log into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.
Source ↗Publisher website ·- Peer review Peer review
Single-blind peer review by two or more anonymous reviewers and the editor. Model summary
Except where otherwise stated, manuscripts are single-blind peer-reviewed by two or more anonymous reviewers and the editor.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
Clinical trials should be prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Please include the name of the trial register and your clinical trial registration number at the end of your abstract. If your trial is not registered or was registered retrospectively, please explain the reasons fo…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bi-monthly
- Founded
- 1979
- ISSN
- 0142-2782
- Electronic ISSN
- 1099-081X
- Latest issue on the website
- Volume 47, Issue 2 (April 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Biopharmaceutics & Drug Disposition
What CAS zone is Biopharmaceutics & Drug Disposition in?
In the 2025 upgraded edition of the CAS Journal Ranking, Biopharmaceutics & Drug Disposition is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Biopharmaceutics & Drug Disposition?
The latest impact factor listed by LetPub is 2.11; CiteScore 4.2, h-index 80.
How long does peer review take at Biopharmaceutics & Drug Disposition?
Based on the dates recorded on 38 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 175 days (interquartile range 117–232 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 13% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Biopharmaceutics & Drug Disposition?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≥ 3; Manuscript length: ≤ 5,000 words; Reference style: APA; First submission: Free format: the journal's layout is not required; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Biopharmaceutics & Drug Disposition based?
Of the 39 board members whose country the journal's board page names, 4 (about 10%) are in mainland China; the countries named most often are United States (12), Japan (7) and Canada (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Biopharmaceutics & Drug Disposition?
According to LetPub and DOAJ records, Biopharmaceutics & Drug Disposition is indexed in SCIE and Scopus. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Biopharmaceutics & Drug Disposition open access, and what is the APC?
Biopharmaceutics & Drug Disposition is a hybrid journal. For open-access publication: APC about USD 3,800.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .